✦ LIBER ✦

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

✍ Scribed by George Somlo; Ashkan Lashkari; William Bellamy; Todd M. Zimmerman; Joseph M. Tuscano; Margaret R. O’Donnell; Ann F. Mohrbacher; Stephen J. Forman; Paul Frankel; Helen X. Chen; James H. Doroshow; David R. Gandara

Book ID: 108677205
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 88 KB
Volume: 154
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2011.08623.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined bendamustine, prednisolone and

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

✍ Wolfram Pönisch; Marta Rozanski; Hartmut Goldschmidt; Franz Albert Hoffmann; Tho 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Thalidomide has limited single-agent act

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

✍ Sonali M. Smith; David Grinblatt; Jeffrey L. Johnson; Donna Niedzwiecki; David R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB